Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2-Reference-Cited by-同舟云学术

Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2

Published:2014-10-08 Issue:20 Volume:57 Page:8378-8397
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Maeda Dean Y.¹,Peck Angela M.¹,Schuler Aaron D.¹,Quinn Mark T.²,Kirpotina Liliya N.²,Wicomb Winston N.³,Fan Guo-Huang⁴,Zebala John A.¹

Affiliation:

1. Syntrix Biosystems, 215 Clay Street, Auburn, Washington 98001, United States

2. Department of Microbiology and Immunology, Montana State University, 960 Technology Boulevard, Bozeman, Montana 59717, United States

3. Infectious Disease Research Institute, 1616 Eastlake Avenue East, Seattle, Washington 98102, United States

4. Department of Pharmacology, Meharry Medical College, 1005 Dr. DB Todd Boulevard, Nashville, Tennessee 37208, United States

Funder

National Heart, Lung, and Blood Institute

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm500827t

Reference65 articles.

1. Gαi Is Not Required for Chemotaxis Mediated by Gi-coupled Receptors

2. A comparison of post-receptor signal transduction events in Jurkat cells transfected with either IL-8R1 or IL-8R2 Chemokine mediated activation of p42/p44 MAP-kinase (ERK-2)

3. Mechanisms of IL-8-induced Ca2+ signaling in human neutrophil granulocytes

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Myeloid-Derived Suppressor Cell Trafficking as a Novel Immunotherapeutic Approach in Microsatellite Stable Colorectal Cancer;Cancers;2023-11-20

2. CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth;Molecular Cancer;2023-06-03

3. Therapeutic inhibition of CXCR1/2: where do we stand?;Internal and Emergency Medicine;2023-05-30

4. Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers;European Journal of Medicinal Chemistry;2023-03

5. CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth;2023-02-22